Table 2 Clinical characteristics of the... | American Society of Hematology

Table 2

Clinical characteristics of the 29 ML-DS patients at induction failure or at relapse

	No	%
Disease status
Refractory AML	3	10.3
Relapsed AML	26	89.7
Duration from initial diagnosis to relapse, mo (n = 26)
Median (range)	8.6 (2.4-71.8)
< 6	8	30.8
≤ 6 to < 12	13	50.0
≤ 12	5	19.2
Site of relapse (n = 26)
Bone marrow	25	96.2
Extramedullary (skin)	1	3.8
FAB classification at relapse (n = 26)
M1	1*	3.8
M7	23†	88.5
Not available	2‡	7.7
Karyotype at relapse (n = 26)
Same as before	10	38.5
Additional abnormalities	12	46.1
Not available	4	15.4

	No	%
Disease status
Refractory AML	3	10.3
Relapsed AML	26	89.7
Duration from initial diagnosis to relapse, mo (n = 26)
Median (range)	8.6 (2.4-71.8)
< 6	8	30.8
≤ 6 to < 12	13	50.0
≤ 12	5	19.2
Site of relapse (n = 26)
Bone marrow	25	96.2
Extramedullary (skin)	1	3.8
FAB classification at relapse (n = 26)
M1	1*	3.8
M7	23†	88.5
Not available	2‡	7.7
Karyotype at relapse (n = 26)
Same as before	10	38.5
Additional abnormalities	12	46.1
Not available	4	15.4

AML indicates acute myeloid leukemia; FAB, French-American-British; and MDS, myelodysplastic syndrome.

This patient was M7 at initial diagnosis.

A total of 18 patients were M7, 1 was M1, 3 were MDS, and 1 unknown at initial diagnosis.

One patient was M5a, and 1 was M7 at initial diagnosis.